(Q36903751)

17 August 2017

1 reference

title

Bevacizumab: in first-line treatment of metastatic breast cancer (English)

1 reference

17 August 2017

1 reference

1

Lesley J Scott

1 reference

17 August 2017

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

67

1 reference

17 August 2017

12

1 reference

17 August 2017

1793-1799

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767120-00009

17 August 2017

0 references

cites work

Targeted therapies for cancer 2004.

1 reference

12 December 2020

E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer

1 reference

12 December 2020

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

1 reference

12 December 2020

Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.

1 reference

12 December 2020

Vascular endothelial growth factor: basic science and clinical progress

1 reference

12 December 2020

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

1 reference

12 December 2020

Complexation of VEGF with bevacizumab decreases VEGF clearance in rats

1 reference

12 December 2020

Molecular approach to breast cancer treatment

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Monoclonal antibodies as therapeutic agents for cancer

1 reference

12 December 2020

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

12 December 2020

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

12 December 2020

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

12 December 2020

10.2165/00003495-200767120-00009

Identifiers

DOI

1 reference

PubMed ID

17683175

Dimensions Publication ID

17 August 2017

0 references

1 reference

PubMed ID

17683175